Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs) -- Ignore unavailable to you. Want to Upgrade?

To: William Strop who wrote (1247)	6/3/2000 4:56:00 PM
From: Scott H. Davis	Respond to of 1972

FYI all, I was given this by another investor I touch basis with, who's a prime time snipper. (William, ya doing OK? been awhile. Thought we'd see a little more response from the cancer conference, oh well, do like the recent news on the preventative V front) Vical (VICL) 18 +5/16: Just another victim of the biotech bloodbath, VICL has dropped from a high of 73 1/2 set back in late February. That's a decline of 76%! While the last few months have been dreadful, it is important to realize that long-term investors in this stock have done quite well. If you owned VICL a year-ago, you would be sitting on a handsome gain of 50% - even after the recent carnage. And unlike many of the third tier biotech stocks that surged during the industry-wide rally regardless of fundamentals, VICL is a quality company that gets high marks in Briefing.com's screening process. For those of you that haven't followed our reports on the biotech industry, we look for companies with enough cash to cover their burn rates for at least 1 1/2 years (preferably two); drugs in the later stages of clinical development; numerous collaborative agreements with major pharmaceutical companies; and a proven management team with a record of successfully meeting milestones/earnings. Our only concern with VICL is on the latter front, as the company's President & CEO will step down at the end of next month. Until the company selects a permanent replacement, investors are likely to take a wait-and-see approach to the stock. As for the rest of the picture, VICL continues to hit on all cylinders as Allovectin-7, Leuvectin and Vaxid trials are proceeding on plan. The company also announced a collaborative deal with Human Genome (HGSI) in February. Finally, VICL is sitting on plenty of cash. Basically, as long as the company doesn't screw up in selecting a new President & CEO, VICL is well positioned to resume its long-term uptrend... Our 12- to 18-mo target is 32. -- Robert Walberg, Briefing.com